Characteristic | All Randomized (Nā=ā533) | Minimal Contact enrollment (Nā=ā306) | Acute Episodic Care enrollment (Nā=ā227) | p-value# |
---|---|---|---|---|
Enrollment Locationāno. (%) | Ā | Ā | Ā | Ā |
āEmergency department visit | 95 (17.8) | - | 95 (41.9) | Ā |
āUrgent care visit | 23 (4.3) | - | 23 (10.1) | Ā |
āMonoclonal antibody or COVID clinic visit | 88 (16.5) | - | 88 (38.8) | Ā |
āOther urgent clinic visits | 21 (3.9) | - | 21 (9.3) | Ā |
āLow/No- Touch enrollment | 306 (57.4) | 306 (100.0) | - | Ā |
Median time from COVID test to randomization (IQR)ādays | 6.0 (3.0, 10.0) | 9.0 (5.0, 12.0) | 3.0 (1.0, 6.0) | <ā0.001 |
Participants who initiated trial treatmentāno. | 458 | 280 | 178 | Ā |
āMedian time from COVID test to ātreatment initiation (IQR)ādays | 11.0 (7.0, 14.0) | 13.0 (10.0, 15.0) | 8.0 (5.0, 11.0) | <ā0.001 |
āMedian time from randomization to ātreatment initiation (IQR)ādays | 3.0 (2.0, 5.0) | 3.0 (2.0, 5.0) | 3.0 (2.0, 5.0) | 0.62 |
Median age (IQR*)āyr | 54.0 (46.0, 59.0) | 52.0 (45.0, 58.0) | 55.0 (48.0, 60.0) | 0.005 |
Sexāno. (%) | Ā | Ā | Ā | Ā |
āFemale | 311 (58.4) | 183 (59.8) | 128 (56.4) | 0.43 |
āMale | 222 (41.7) | 123 (40.2) | 99 (43.6) | Ā |
Race / ethnicity āno. (%) | Ā | Ā | Ā | Ā |
āBlack non-Hispanic | 61 (11.4) | 19 (6.2) | 42 (18.9) | <ā0.001 |
āHispanic | 98 (18.4) | 32 (10.5) | 66 (29.1) | Ā |
āWhite non-Hispanic | 339 (63.6) | 231 (75.5) | 108 (47.6) | Ā |
āOther** | 35 (6.6) | 24 (7.8) | 11 (4.9) | Ā |
Region-no (%) | Ā | Ā | Ā | Ā |
āNortheast | 47 (8.8) | 40 (13.1) | 7 (3.1) | <ā0.001 |
āMidwest | 77 (14.5) | 37 (12.1) | 40 (17.6) | Ā |
āSouth | 236 (44.3) | 59 (19.3) | 177 (78.0) | Ā |
āWest | 173 (32.5) | 170 (55.6) | 3 (1.3) | Ā |
Median body mass index (IQR)ākg/m2 | 30.1 (26.0, 35.4) | 29.3 (25.5, 33.9) | 31.4 (27.3, 37.7) | <ā0.001 |
History of DVT or PE ā no. (%) | 19 (3.6) | 12 (3.9) | 7 (3.1) | 0.61 |
Hypertensionāno. (%) | 179 (33.6) | 82 (26.8) | 97 (42.7) | <ā0.001 |
Diabetesāno. (%) | 102 (19.1) | 43 (14.1) | 59 (26.0) | <ā0.001 |
History of smokingāno. (%) | 120 (22.5) | 65 (21.2) | 55 (24.2) | 0.41 |
Median Platelet count (IQR)āper mm [3] | 239.0 (189.0, 307.0) | 274.0 (215.0, 329.0) | 211.5 (169.0, 251.0) | <ā0.001 |
Median creatinine clearance (IQR)āmg/ml/1.73m2 | 114.5 (91.3, 144.6) | 113.0 (91.4, 144.7) | 117.0 (91.0, 144.4) | 0.5 |
D-dimerāno. (%)*** | 478 | 264 | 214 | Ā |
āā¤1 X upper limit of normal | 313 (65.5) | 174 (65.9) | 139 (65.0) | 0.82 |
ā>1 - ā¤2 X upper limit of normal | 115 (24.1) | 61 (23.1) | 54 (25.2) | Ā |
ā>2 X upper limit of normal | 50 (10.5) | 29 (11.0) | 21 (9.8) | Ā |
Median hsCRP (IQR)āmg/L | 4.0 (1.5, 12.5) | 3.0 (1.3, 10.0) | 6.0 (1.9, 31.3) | <ā0.001 |